Indraprastha Medical Q4 FY26 results on May 12, 2026

Board meeting set for May 12

Indraprastha Medical Corporation Limited has informed stock exchanges that its Board of Directors will meet on Tuesday, May 12, 2026. The meeting is scheduled to consider and approve the company’s audited financial results for the quarter and year ended March 31, 2026. The board will also consider and recommend a dividend, if any, on the equity shares for the financial year 2025-26. The intimation has been filed with BSE and referenced for regulatory compliance under SEBI’s listing rules. For shareholders, the meeting is a key calendar event because it determines the audited year-end numbers and any final dividend proposal. The company has positioned the agenda as two specific items: audited results approval and dividend deliberation. The filing does not include financial figures for Q4 or the full year, as those will be taken up in the meeting.

Agenda: audited FY26 numbers and dividend, if any

The company’s exchange communication states the board will consider and approve the audited financial results for the quarter and year ended March 31, 2026. Because this is the year-end audit cycle, the board’s approval typically precedes publication of results and related reports. Alongside the audited numbers, directors will deliberate on a dividend recommendation for FY 2025-26. The company has explicitly stated that the dividend is not guaranteed, using the phrase “dividend, if any.” If recommended, the dividend would be for equity shareholders and would be linked to the financial year 2025-26. The update is framed as a board meeting intimation and not an outcome, so it does not specify the size of any potential payout. Investors usually track such board meetings for the sequence of disclosures that follow after approval.

What the company told BSE and NSE under SEBI rules

Indraprastha Medical has linked the disclosure to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Regulation 29 is the framework that requires listed companies to provide prior intimation of board meetings where financial results or dividends will be considered. Separately, the company’s earlier board meeting outcomes cited Regulations 30 and 33 read with Schedule III, which govern event disclosures and financial results reporting. In its February 2026 outcome note, the company referenced Regulation 30 and 33 for the board’s approvals. For the May 12 meeting, the focus is Regulation 29 because it is an intimation ahead of time. The filing confirms the meeting date and the agenda items, which is what investors and exchanges typically rely on for compliance checks. The company has also indicated that the communication is meant “for your information and record,” in line with standard exchange filings.

Key details at a glance

The board meeting is set for Tuesday, May 12, 2026. The agenda covers both the audited financial results for Q4 and the full year ended March 31, 2026, and a possible dividend recommendation for FY 2025-26. This is aligned with the company’s past pattern of considering audited results and dividend in a May board meeting. In FY 2024-25, Indraprastha Medical’s board meeting on May 16, 2025 approved audited financial statements for the year ended March 31, 2025 and recommended a dividend. That prior recommendation was a dividend at 45%, stated as Rs 4.50 per share for FY 2024-2025. The company has not stated whether it will follow a similar payout approach for FY 2025-26. As of this announcement, only the meeting and the agenda are confirmed.

Context from the February 2026 board meeting

Indraprastha Medical’s last detailed board meeting outcome in the provided disclosures was dated February 3, 2026. At that meeting, the board considered and approved unaudited financial results for the quarter and nine months ended December 31, 2025, along with the limited review report from the statutory auditors. The company also noted an additional affidavit filed by the Government of NCT of Delhi in a pending “Free Patient Matter” related to SLP (C) No. 29482/2009, concerning the lease of land for the Sarita Vihar hospital. The filing said the company was reviewing the affidavit and would take appropriate steps. The same meeting also included board and governance changes: appointment of Mr. Harsh Pati Singhania as an additional director in the category of Non-executive Independent Director for five years, subject to shareholder approval. It further recorded re-appointments of independent directors Mr. Salil Singhal and Ms. Vineeta Rai for second terms of five years from February 8, 2026, and Ms. Madhumita Ganguli for a second term from June 9, 2026, each subject to shareholder approval through special resolution. The meeting timing was disclosed as commencing at 3:00 p.m. and concluding at 5:10 p.m.

Dividend track record: what was last recommended

The most recent dividend figure mentioned in the disclosures relates to FY 2024-25. On May 16, 2025, the board approved the audited financial statements for the year ended March 31, 2025 and audited results for the quarter and year ended March 31, 2025. In the same decision, the board recommended a dividend at 45%, described as Rs 4.50 per share for FY 2024-2025. For FY 2025-26, the board will consider a dividend proposal on May 12, 2026, but the company has not specified any amount in the intimation. The company’s language leaves the decision open, stating it will “consider and recommend dividend, if any.” Shareholders typically look for the board’s outcome filing after the meeting for any confirmation. Any recommendation, if made, would be part of the formal board outcome and subsequent corporate action disclosures.

Credit rating and borrowing disclosures in recent filings

Indraprastha Medical has also disclosed credit rating actions in earlier updates. One filing states that ICRA Limited reaffirmed a long-term fund-based cash credit rating of {ICRA}AA for bank facilities of ₹32.50 crore and a short-term non-fund-based rating of {ICRA}A1+ for ₹30 crore facilities. The same disclosure states ICRA assigned a long-term fund-based term loan rating of {ICRA}AA for ₹100 crore to the company. In a separate “Large Corporate” initial disclosure format, the company also reported outstanding borrowing of ₹0.00 crore as on March 31 or December 31, as applicable, within that template. These disclosures provide context on the company’s reported credit profile in filings, though they are separate from the May 12 agenda. The May 12 meeting, as communicated, is limited to audited financial results and dividend consideration.

What to watch after the board meeting

After the May 12, 2026 meeting concludes, investors typically expect an outcome filing confirming whether audited results were approved and whether a dividend was recommended. The company’s earlier disclosures indicate results are published in newspapers and posted on the company website after approval, at least in the case of the February 2026 unaudited results. For May 12, the outcome would be the first official record of audited Q4 FY26 and full-year FY26 numbers in the current cycle, based on the agenda disclosed. Separately, if a dividend is recommended, the market usually watches for details such as the per-share amount and any relevant dates in subsequent corporate action communication. The filing itself also includes a stock move figure of -11.30 (-2.93%), highlighting that investors are tracking price action around corporate updates. However, the meeting intimation does not attribute that move to any single factor.

Conclusion

Indraprastha Medical’s board meeting on May 12, 2026 will focus on approving audited financial results for the quarter and year ended March 31, 2026 and considering a dividend recommendation for FY 2025-26. The company has communicated the schedule under SEBI Regulation 29 through exchange filings. Investors will look to the post-meeting outcome disclosure for audited numbers and any final dividend recommendation, if approved.